60 Degrees Pharmaceuticals, Inc. (SXTP): R&D Expense
$2.11M
Year ended 2025-12-31
+58.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.11M | -57.8% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $4.99M | +620.8% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $691.8K | +31.6% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $525.6K | n/a | 2024-04-01, From 2022-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $2.11M | -57.8% |
| Shattuck Labs, Inc. (STTK) | 2025-12-31 | $35.27M | -47.5% |
| Dare Bioscience, Inc. (DARE) | 2025-12-31 | $5.52M | -61.4% |
| Rafael Holdings, Inc. (RFL) | 2025-07-31 | $12.82M | +207.5% |
| Neuphoria Therapeutics Inc. (NEUP) | 2025-06-30 | $9.01M | -4.4% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Longeveron Inc. (LGVN) | 2025-12-31 | $12.04M | +48.0% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
Compare SXTP, STTK, DARE, RFL side by side · Screen every company in Pharmaceutical Preparations ↗